Macrolide-theophylline interactions: No role for the inhibition of cytochrome P4501A2

British Journal of Clinical Pharmacology

Volumn 66, Issue 6, 2008, Pages 898-900

  Polasek, Thomas M ^a   Miners, John O ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; AZITHROMYCIN; CAFFEINE; CLARITHROMYCIN; CYTOCHROME P450 1A2; DEXAMETHASONE; DILTIAZEM; ERYTHROMYCIN; KETOCONAZOLE; MACROLIDE; MIDAZOLAM; PHENACETIN O DEETHYLASE; ROXITHROMYCIN; THEOPHYLLINE; TROLEANDOMYCIN; VERAPAMIL; WARFARIN;

DRUG CLEARANCE; DRUG DISPOSITION; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; FOOD DRUG INTERACTION; GRAPEFRUIT; HUMAN; LETTER; LIVER MICROSOME; METABOLIC CLEARANCE RATE; PRIORITY JOURNAL;

CYTOCHROMES; DRUG INTERACTIONS; HUMANS; MACROLIDES; THEOPHYLLINE;

EID: 56549112866     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03299.x     Document Type: Letter

References (22)

1. Rossi S, Vitri A, Hurley E, Abbott F. Australian Medicines Handbook, 6th edn. Adelaide : The Royal Australian College of General Practitioners, the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, and the Pharmaceutical Society of Australia, 2008.
2. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides erratum appears in Clin Pharmacokinet 1993; 24: 70 Clin Pharmacokinet 1992 23 : 106 31.
3. Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 2000 50 : 285 95.
4. Miners JO, McKinnon RA. CYP1A. In : Metabolic Drug Interactions, 1st edn, eds Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M. Philidelphia, PA : Lippincott Williams & Wilkins, 2000 61 73.
5. Yamazaki H, Shimada T. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos 1998 26 : 1053 7.
6. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 2006 316 : 336 48.
7. Bruce MA, Hall SD, Haehner-Daniels BD, Gorski JC. In vivo effect of clarithromycin on multiple cytochrome P450s. Drug Metab Dispos 2001 29 : 1023 8.
8. Polasek TM, Miners JO. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A probe substrate. Eur J Clin Pharmacol 2006 62 : 203 08.
9. Polasek TM, Miners JO. In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opin Drug Metab Toxicol 2007 3 : 321 29.
10. Polasek TM, Elliot DJ, Somogyi AA, Gillam EM, Lewis BC, Miners JO. An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol 2006 61 : 570 84.
11. Obach RS, Walsky RL, Venkatakrishnan K. Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 2007 35 : 246 55.
12. Rasmussen BB, Brøsen K. Theophylline has no advantages over caffeine as a putative model drug for assessing CYP1A2 activity in humans. Br J Clin Pharmacol 1997 43 : 253 58.
13. Tassaneeyakul W, Birkett DJ, McManus ME, Tassaneeyakul W, Veronese ME, Andersson T, Tukey RH, Miners JO. Caffeine metabolism by human hepatic cytochromes P450: contributions of CYP1A2, 2E1 and 3A isoforms. Biochem Pharmacol 1994 47 : 1767 76.
14. Tjia JF, Colbert J, Back DJ. Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther 1996 276 : 912 7.
15. Robson RA, Miners JO, Mathews AP, Stupans I, Meller D, McManus ME, Birkett DJ. Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies. Biochem Pharmacol 1988 37 : 1651 59.
16. Birkett DJ, Miners JO. Methylxanthines. In : Metabolic Drug Interactions, 1st edn, eds Levy RH, Thummel K, Trager WF, Hansten PD, Eichelbaum M. Philidelphia, PA : Lippincott Williams & Wilkins, 2000 469 82.
17. Brown MW, Maldonado AL, Meredith CG, Speeg KV. Effect of ketoconazole on hepatic oxidative drug metabolism. Clin Pharmacol Ther 1985 37 : 290 97.
18. Fuhr U, Maier A, Keller A, Steinijans VW, Sauter R, Staib AH. Lack of effect of grapefruit juice on theophylline pharmacokinetics. Int J Clin Pharmacol Ther 1995 33 : 311 14.
19. Sirmans SM, Pieper JA, Lalonde RL, Smith DG, Self TH. Effects of calcium channel blockers on theophylline disposition. Clin Pharmacol Ther 1988 44 : 29 34.
20. Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, Yamamoto T. Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in human liver. Drug Metab Dispos 2005 33 : 619 22.
21. Eberl S, Renner B, Neubert A, Reisig M, Bachmakov I, König J, Dörje F, Mürdter TE, Ackermann A, Dormann H, Gassmann KG, Hahn EG, Zierhut S, Brune K, Fromm MF. Role of P-glycoprotein inhibition for drug interactions. Evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet 2007 46 : 1039 49.
22. Seithel A, Eberl S, Singer K, Auge D, Heinkele G, Wolf NB, Dörje F, Fromm MF, König J. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 2007 35 : 779 89.